Home / Companies / Celltrion Hungary
Company family
Celltrion Hungary: medicine shortages
As of 2 Nov 2026, 26 Celltrion Hungary products have a reported shortage across 4 countries, covering 8 medicines.
Products short26rank #83 of 464
Medicines8active ingredients
Countries4/16
New in 90 days19+13 vs market pace
Typical duration34 daysmedian so far
Manufacturing0%demand-driven 91%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Omalizumab | 10 | 30 Sep 2026 | Increased demand | 4/16 | |
| Infliximab | 5 | 10 Aug 2026 | Increased demand | 2/16 | |
| Adalimumab | 4 | 11 Mar 2026 | Increased demand | 8/16 | |
| Denosumab | 2 | 9 Jun 2026 | Increased demand | 2/16 | |
| Tocilizumab | 2 | 15 Sep 2026 | Increased demand | 5/16 | |
| Bevacizumab | 1 | 1 May 2026 | Increased demand | 1/16 | |
| Rituximab | 1 | 5 Jul 2026 | Increased demand | 2/16 | |
| Ustekinumab | 1 | 7 Oct 2026 | Not stated | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.